The purpose of this guidance is to clarify circumstances under which the FDA’s Center for Drug Evaluation and Research (CDER) may refuse to file a new drug application (NDA) or supplemental NDA (21 CFR 314.101(d)) or a biologics license application (BLA) or supplemental BLA (21 CFR 601.2) for a therapeutic biological product regulated by CDER,2 and to underscore the importance of submitting a complete application to minimize the chance of a refuse-to-file (RTF) action by the FDA. In particular, this guidance focuses on the FDA’s policy for refusing to file an NDA under § 314.101(d)(3) when the NDA is incomplete because it does not on its face contain information required under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) and 21 CFR 314.50
Artigos recentes
- Review and Update of Device Establishment Inspection Processes and Standards
- APORMED publica Orientações para a retoma da interação entre os profissionais da indústria e os profissionais de saúde
- Medicines for Europe “LESSONS LEARNED FROM COVID-19”
- NOVAS REGRAS DE SEGURANÇA
- VAGAS ESGOTADAS na formação Boas Práticas de Distribuição de Medicamentos . Próxima edição 2 e 3 de dezembro
- Estratégia Farmacêutica Europeia em consulta pública
- New Guidance on Good Clinical Practice (GCP)
- Novas formações 2020